Xenon Pharmaceuticals (XENE)

Xenon Pharmaceuticals on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.

Download CSV

Short interest in Xenon Pharmaceuticals (XENE) was 7.4 million shares at the 30 October 2026 settlement, up 0.2% from the 15 October 2026 settlement, with days to cover at 6.4. In the last 90 days Xenon Pharmaceuticals insiders reported 2 open-market purchases and 2 open-market sales, net purchases of $1.3 million. The largest was a purchase of 30,000 shares worth $1.1 million by MORTIMER IAN (PRESIDENT & CEO) on 30 September 2026. The next earnings report for Xenon Pharmaceuticals is estimated for 25 February 2027.

7.4M

Short interest

settlement 2026-10-30

6.4

Days to cover

+2.4 days vs prior

70.9%

Short share of volume

2026-11-12

44,074

Fails to deliver

settlement 2026-10-08

Thu 25 Feb

Next earnings

estimated date

$1.3M

Insider flow, 90 days

2 buys, 2 sells

As of 2026-11-12.

Short interest

FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSON

As of 30 October 2026, short interest in XENE is 7,363,365 shares, up 1,321,878 shares over the last month. Over the last 48 readings it ranged from 2,878,735 shares (29 November 2024) to 7,705,812 shares (30 September 2025). The latest reading sits at the top of that range. At the reported average volume of 1.2M shares a day that is 6.4 days to cover.

Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/xene" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
PreviewDark previewAdd ?theme=dark to the src for a dark chart.
SettlementShares shortChangeAvg daily volumeDays to cover
2026-10-307,363,365+0.2%1,156,9156.36
2026-10-157,348,577+21.6%1,859,0113.95
2026-09-306,041,487-6.3%3,834,8351.58
2026-09-156,444,815+1.6%527,34512.22
2026-08-316,344,135+11.9%698,2759.09
2026-08-145,668,994+5.3%618,6359.16
2026-07-315,384,476-15.0%734,5327.33
2026-07-156,337,096+1.3%1,778,0103.56
2026-06-306,257,737+42.0%2,112,2902.96
2026-06-154,408,157+9.0%1,376,4773.20
2026-05-294,044,948+5.5%1,377,6672.94
2026-05-153,833,400-7.6%947,8464.04
2026-04-304,149,067-14.5%898,7774.62
2026-04-154,854,352+0.1%902,4505.38
2026-03-314,851,044-11.0%1,368,5003.54
2026-03-135,451,476-1.5%3,210,0981.70
2026-02-275,533,096+2.9%816,8746.77
2026-02-135,379,792-2.9%728,8857.38
2026-01-305,541,753+3.2%844,0326.57
2026-01-155,371,266-9.4%1,232,2304.36
2025-12-315,927,441+3.6%719,8828.23
2025-12-155,720,672-2.9%803,3817.12
2025-11-285,889,334-2.5%800,2507.36
2025-11-146,043,619+4.5%819,8587.37
2025-10-315,785,686-5.9%792,3727.30
2025-10-156,148,669-20.2%759,5558.10
2025-09-307,705,812+9.4%799,5119.64
2025-09-157,040,555+1.9%629,72411.18
2025-08-296,908,299+0.2%676,16510.22
2025-08-156,892,652-1.2%1,207,8405.71
2025-07-316,974,859+7.2%821,2758.49
2025-07-156,505,144-11.9%897,9657.24
2025-06-307,386,050+100.1%2,091,6543.53
2025-06-133,690,931+9.6%774,5094.77
2025-05-303,366,401-3.0%1,219,1592.76
2025-05-153,470,297-3.2%1,639,6332.12
2025-04-303,584,868-9.7%724,6044.95
2025-04-153,970,374+0.6%1,152,4543.45
2025-03-313,947,500+8.4%410,2659.62
2025-03-143,641,348-3.2%512,2727.11
2025-02-283,760,703-4.1%533,6697.05
2025-02-143,922,057+11.3%374,86710.46
2025-01-313,523,052-1.9%435,5638.09
2025-01-153,592,815+3.1%401,1678.96
2024-12-313,483,666+20.5%414,0338.41
2024-12-132,890,158+0.4%350,2268.25
2024-11-292,878,735-2.1%437,2766.58
2024-11-152,939,355+1.8%388,9597.56

Daily short volume

FINRA Reg SHO, the last 30 sessions. JSON

As of 12 November 2026, the short share of XENE volume is 70.9%, up 7.1 points over the last five sessions. Over the last 30 readings it ranged from 34.0% (9 November 2026) to 88.3% (2 November 2026). The latest reading is 11.9 points above the 30-session average of 59.0%, on 533K shares reported.

DateShort volumeTotal volumeShort shareExempt
2026-11-12378K533K70.9%0
2026-11-11359K610K58.9%0
2026-11-10443K1.0M43.8%0
2026-11-09203K597K34.0%0
2026-11-06166K300K55.2%4
2026-11-05215K338K63.7%445
2026-11-04562K816K68.9%0
2026-11-03411K507K81.1%1
2026-11-021.1M1.2M88.3%11
2026-10-30340K511K66.5%0
2026-10-29435K807K53.9%0
2026-10-28416K701K59.3%0
2026-10-27319K453K70.3%0
2026-10-26187K241K77.4%0
2026-10-23111K225K49.5%0
2026-10-22205K581K35.2%117
2026-10-21230K346K66.4%222
2026-10-20180K379K47.5%44
2026-10-19372K535K69.6%12
2026-10-16312K454K68.7%1,983
2026-10-15395K630K62.7%0
2026-10-14227K471K48.2%800
2026-10-13282K419K67.3%2,169
2026-10-12142K230K61.9%0
2026-10-09168K374K44.9%0
2026-10-08469K908K51.7%0
2026-10-07364K761K47.9%0
2026-10-06639K1.2M52.8%0
2026-10-05390K696K56.0%407
2026-10-02389K811K47.9%711

Fails to deliver

SEC, the last 30 settlement dates with a fail. JSON

As of 8 October 2026, the fails-to-deliver balance in XENE is 44,074 shares, down 566 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (29 July 2026) to 60,116 shares (26 June 2026).

SettlementShares failedPriceValue
2026-10-0844,074$36.41$1.6M
2026-10-0744,640$36.57$1.6M
2026-10-051$38.02$38
2026-09-01671$60.22$40K
2026-08-2416$60.77$972
2026-08-1316$65.26$1K
2026-08-0325$62.67$2K
2026-07-31322$64.19$21K
2026-07-291$64.94$65
2026-07-283,116$65.78$205K
2026-07-273,651$65.42$239K
2026-07-207$68.26$478
2026-07-1617$67.71$1K
2026-07-149,120$67.72$618K
2026-07-097,660$69.95$536K
2026-07-08582$63.37$37K
2026-06-2660,116$56.78$3.4M
2026-06-2359$54.79$3K
2026-06-081,075$51.73$56K
2026-05-26161$54.17$9K
2026-05-2189$54.68$5K
2026-05-1890$54.39$5K
2026-04-21113$57.09$6K
2026-04-204,206$59.70$251K
2026-04-06325$56.85$18K
2026-03-261,140$55.57$63K
2026-03-2465$54.42$4K
2026-03-113,451$60.61$209K
2026-03-1048,878$62.76$3.1M
2026-03-06670$42.05$28K

Insider trades

SEC Form 4, newest first. JSON

Over the last 90 days XENE insiders reported 2 open-market buys ($1.7M) against 2 sells ($426K), so the dollar flow leans toward buying. Latest filing: Kelly Thomas Patrick (Chief Financial Officer) on 2026-10-15.

DateInsiderTitleTypeSharesPriceValueOwned after
2026-10-15Kelly Thomas PatrickChief Financial OfficerExercise or conversion8Kprice not stated in the filingnot stated23K
2026-09-30MORTIMER IANPRESIDENT & CEOBuy30K$37.38$1.1M50K
2026-09-30Kelly Thomas PatrickChief Financial OfficerBuy15K$37.32$560K15K
2026-09-01Svoronos DawnDirectorExercise or conversion5K$8.15$42K31K
2026-08-28KENNEY CHRISTOPHER JOHNChief Medical OfficerSell700$60.98$43K2
2026-08-28KENNEY CHRISTOPHER JOHNChief Medical OfficerSell6K$60.17$383K702
2026-08-11GANNON STEVENDirectorSell10K$64.06$641K2K
2026-06-05PATOU GARYDirectorSell1K$53.14$70K25K
2026-06-05Cannon GillianDirectorSell1K$53.14$63K1K
2026-06-01Svoronos DawnDirectorTax withholding1K$53.41$76K26K
2026-06-01Svoronos DawnDirectorExercise or conversion3Kprice not stated in the filingnot stated28K
2026-06-01Cannon GillianDirectorExercise or conversion3Kprice not stated in the filingnot stated3K
2026-06-01GANNON STEVENDirectorExercise or conversion3Kprice not stated in the filingnot stated13K
2026-06-01GANNON STEVENDirectorTax withholding1K$53.41$76K12K
2026-06-01GAROFALO ELIZABETH A.DirectorExercise or conversion3Kprice not stated in the filingnot stated3K
2026-06-01Gover Justin D.DirectorExercise or conversion3Kprice not stated in the filingnot stated3K
2026-06-01Machado PatrickDirectorExercise or conversion3Kprice not stated in the filingnot stated3K
2026-06-01PATOU GARYDirectorExercise or conversion3Kprice not stated in the filingnot stated26K
2026-05-12GANNON STEVENDirectorExercise or conversion4K$7.38$26K11K
2026-03-13MORTIMER IANPRESIDENT & CEOSell7K$55.23$404K20K
2026-03-13DiFabio AndreaChief Legal OfficerSell1K$55.23$74K7K
2026-03-13KENNEY CHRISTOPHER JOHNChief Medical OfficerSell1K$55.23$78K7K
2026-03-12MORTIMER IANPRESIDENT & CEOExercise or conversion13Kprice not stated in the filingnot stated27K
2026-03-12DiFabio AndreaChief Legal OfficerExercise or conversion4Kprice not stated in the filingnot stated9K
2026-03-12KENNEY CHRISTOPHER JOHNChief Medical OfficerExercise or conversion4Kprice not stated in the filingnot stated8K
2026-03-10MORTIMER IANPRESIDENT & CEOSell11K$60.11$677K15K
2026-03-10DiFabio AndreaChief Legal OfficerSell3K$60.11$157K5K
2026-03-10KENNEY CHRISTOPHER JOHNChief Medical OfficerSell3K$60.11$167K5K
2026-03-09MORTIMER IANPRESIDENT & CEOExercise or conversion20Kprice not stated in the filingnot stated26K
2026-03-09DiFabio AndreaChief Legal OfficerExercise or conversion8Kprice not stated in the filingnot stated8K
2026-03-09KENNEY CHRISTOPHER JOHNChief Medical OfficerExercise or conversion8Kprice not stated in the filingnot stated8K
2026-03-09MORTIMER IANPRESIDENT & CEOSell65K$62.06$4.0M6K
2026-03-09MORTIMER IANPRESIDENT & CEOExercise or conversion65K$9.44$614K71K
2026-03-09MORTIMER IANPRESIDENT & CEOSell62K$60.08$3.7M6K
2026-03-09MORTIMER IANPRESIDENT & CEOSell43K$59.26$2.6M73K
2026-03-09MORTIMER IANPRESIDENT & CEOExercise or conversion105K$4.75$499K111K
2026-03-09MORTIMER IANPRESIDENT & CEOSell2K$61.26$150K6K
2026-03-09MORTIMER IANPRESIDENT & CEOSell10K$60.47$609K8K
2026-03-09MORTIMER IANPRESIDENT & CEOSell12K$59.50$743K19K
2026-03-09MORTIMER IANPRESIDENT & CEOExercise or conversion25K$3.10$78K31K
2026-03-09MORTIMER IANPRESIDENT & CEOSell22K$60.49$1.3M6K
2026-03-09MORTIMER IANPRESIDENT & CEOSell32K$59.88$1.9M28K
2026-03-09MORTIMER IANPRESIDENT & CEOSell22K$58.81$1.3M59K
2026-03-09MORTIMER IANPRESIDENT & CEOExercise or conversion75K$8.40$630K81K
2026-01-02MORTIMER IANPRESIDENT & CEOSell2K$44.93$93K6K
2026-01-02MORTIMER IANPRESIDENT & CEOSell38K$44.40$1.7M8K
2026-01-02MORTIMER IANPRESIDENT & CEOExercise or conversion40K$7.49$300K46K
2025-12-08MORTIMER IANPRESIDENT & CEOSell2K$46.32$93K6K
2025-12-08MORTIMER IANPRESIDENT & CEOSell9K$45.59$402K8K
2025-12-05MORTIMER IANPRESIDENT & CEOSell14K$45.03$647K17K
2025-11-28MORTIMER IANPRESIDENT & CEOSell97$45.01$4K31K
2025-10-01MORTIMER IANPRESIDENT, CEO & INTERIM CFOSell25K$40.16$1.0M31K
2025-10-01MORTIMER IANPRESIDENT, CEO & INTERIM CFOExercise or conversion25K$7.69$192K56K
2025-06-05GANNON STEVENDirectorSell3$30.48$917K
2025-05-14GANNON STEVENDirectorExercise or conversion5K$12.57$65K7K
2025-01-27MORTIMER IANPRESIDENT & CEOExercise or conversion15K$17.76$269K46K
2025-01-27MORTIMER IANPRESIDENT & CEOSell1K$41.07$47K31K
2025-01-27MORTIMER IANPRESIDENT & CEOSell15K$40.46$614K31K
2025-01-27MORTIMER IANPRESIDENT & CEOExercise or conversion1K$17.76$20K32K
2025-01-24MORTIMER IANPRESIDENT & CEOSell22K$40.20$903K31K
2025-01-24MORTIMER IANPRESIDENT & CEOExercise or conversion22K$17.76$399K54K
2025-01-23MORTIMER IANPRESIDENT & CEOSell16K$40.08$650K31K
2025-01-23MORTIMER IANPRESIDENT & CEOExercise or conversion16K$17.76$288K48K
2024-12-18AULIN SHERRYChief Financial OfficerSell7K$41.23$297K0
2024-12-18AULIN SHERRYChief Financial OfficerSell12K$41.19$474K0
2024-12-18AULIN SHERRYChief Financial OfficerExercise or conversion9K$9.44$88K9K
2024-12-18AULIN SHERRYChief Financial OfficerExercise or conversion16K$11.58$185K16K
2024-12-18AULIN SHERRYChief Financial OfficerTax withholding4K$41.28$185K12K
2024-12-18AULIN SHERRYChief Financial OfficerTax withholding2K$41.28$88K7K
2024-11-22PATOU GARYDirectorSell3K$41.11$117K24K
2024-11-22PATOU GARYDirectorTax withholding1K$39.80$42K26K
2024-11-22PATOU GARYDirectorExercise or conversion3K$13.48$42K27K
2024-11-22PATOU GARYDirectorSell2K$41.05$84K24K
2024-11-22PATOU GARYDirectorTax withholding649$39.80$26K26K
2024-11-22PATOU GARYDirectorExercise or conversion4K$7.38$26K27K
2024-03-08GAROFALO ELIZABETH A.DirectorTax withholding1K$46.16$65K2K
2024-03-08GAROFALO ELIZABETH A.DirectorSell2K$45.69$96K0
2024-03-08GAROFALO ELIZABETH A.DirectorExercise or conversion4K$18.56$65K4K
2024-03-07GANNON STEVENDirectorSell5K$46.25$231K9K
2024-03-07GANNON STEVENDirectorSell1K$46.45$46K14K
2024-03-07GANNON STEVENDirectorSell2K$46.20$92K2K
2024-03-07GANNON STEVENDirectorSell5K$46.30$232K4K
2024-03-07ROBIN SHERRINGTONEVP, Strategy & InnovationSell1K$46.15$47K15K
2024-03-07ROBIN SHERRINGTONEVP, Strategy & InnovationTax withholding1K$45.96$59K16K
2024-03-07ROBIN SHERRINGTONEVP, Strategy & InnovationTax withholding215$45.96$10K9K
2024-03-07ROBIN SHERRINGTONEVP, Strategy & InnovationExercise or conversion1K$9.85$12K10K
2024-03-07ROBIN SHERRINGTONEVP, Strategy & InnovationSell6K$46.30$283K8K
2024-03-07ROBIN SHERRINGTONEVP, Strategy & InnovationExercise or conversion7K$9.85$73K17K
2023-12-29ROBIN SHERRINGTONEVP, Strategy & InnovationOther transaction8K$0.00$08K
2023-12-19AZAB MOHAMMADDirectorExercise or conversion3K$9.85$34K74K
2023-12-19AZAB MOHAMMADDirectorExercise or conversion823$9.85$8K71K
2023-12-14PATOU GARYDirectorSell8K$41.05$312K5K
2023-12-13PATOU GARYDirectorSell5K$38.94$199K24K
2023-12-13PATOU GARYDirectorExercise or conversion6K$9.85$63K30K
2023-12-13PATOU GARYDirectorTax withholding1K$39.68$51K29K
2023-12-13PATOU GARYDirectorSell8K$41.05$312K5K
2023-12-13PATOU GARYDirectorExercise or conversion3K$9.85$28K26K
2023-12-13PATOU GARYDirectorTax withholding577$39.68$23K26K
2023-12-13PATOU GARYDirectorSell4K$39.84$158K24K
2023-12-13PATOU GARYDirectorTax withholding1K$39.68$46K28K

Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.

Planned sales (Form 144)

Newest first. JSON

17 Form 144 notices on file for XENE worth $23.1M at the prices reported; 1 in the last 90 days worth $438K. Latest: CHRISTOPHER KENNEY filed on 2026-08-28 to sell 7,068 shares ($438K) from 2026-08-28.

FiledSellerSharesMarket valueOf outstandingSale fromBroker
2026-08-28CHRISTOPHER KENNEYOfficer7K$438K0.007%2026-08-28Morgan Stanley Smith Barney LLC Executive Financial Services
2026-08-13STEVEN GANNONDirector10K$641K0.010%2026-08-11RBC Wealth Management
2026-06-05GARY PATOUDirector1K$70K0.001%2026-06-05Morgan Stanley Smith Barney LLC Executive Financial Services
2026-06-05GILLIAN CANNONDirector1K$63K0.001%2026-06-05Morgan Stanley Smith Barney LLC Executive Financial Services
2026-03-13IAN MORTIMEROfficer, Director7K$404K0.009%2026-03-13Morgan Stanley Wealth Management Canada Inc.
2026-03-13CHRISTOPHER JOHN KENNEYOfficer1K$78K0.002%2026-03-13Morgan Stanley Wealth Management Canada Inc.
2026-03-13ANDREA DIFABIOOfficer1K$74K0.002%2026-03-13Morgan Stanley Wealth Management Canada Inc.
2026-03-10IAN MORTIMEROfficer, Director11K$677K0.014%2026-03-10Morgan Stanley Wealth Management Canada Inc.
2026-03-10CHRISTOPHER JOHN KENNEYOfficer3K$167K0.003%2026-03-10Morgan Stanley Wealth Management Canada Inc.
2026-03-10ANDREA DIFABIOOfficer3K$157K0.003%2026-03-10Morgan Stanley Wealth Management Canada Inc.
2026-03-09IAN MORTIMEROfficer, Director270K$16.3M0.325%2026-03-09Canaccord Genuity Corp.
2026-01-02IAN MORTIMEROfficer, Director40K$1.8M0.052%2026-01-02Canaccord Genuity Corp.
2025-12-08IAN MORTIMEROfficer, Director11K$495K0.014%2025-12-08Canaccord Genuity Corp.
2025-12-05IAN MORTIMEROfficer, Director14K$647K0.019%2025-12-05Canaccord Genuity Corp.
2025-12-01IAN MORTIMEROfficer, Director97$4K0.000%2025-11-28Canaccord Genuity Corp.
2025-10-01IAN MORTIMEROfficer, Director25K$1.0M0.032%2025-10-01Canaccord Genuity Corp.
2025-09-19SHERRY AULINFormer officer3K$94K0.003%2025-09-19Morgan Stanley Wealth Management Canada Inc.

Large holders (13D and 13G)

One row per reporting person with its latest filing, newest first. JSON

6 holders report 5% or more of XENE in their latest filing, all on Schedule 13G (passive). The largest reported stake is Abigail P. Johnson at 11.5% of the class (11,136,649 shares), filed 2026-11-05 for an event on 2026-09-30.

FiledFormHolderSharesOf classEvent
2026-11-0613G/Ano. 1T. Rowe Price Investment Management, Inc.investment adviser10.0M10.3%2026-10-31
2026-11-0513G/Ano. 9Abigail P. Johnsonindividual11.1M11.5%2026-09-30
2026-11-0513G/Ano. 9FMR LLCparent holding company11.1M11.5%2026-09-30
2026-08-1313G/Ano. 1Wellington Management Group LLPparent holding company1.4M1.5%2026-06-30
2026-08-1313G/Ano. 1Wellington Group Holdings LLPparent holding company1.4M1.5%2026-06-30
2026-08-1313G/Ano. 1Wellington Investment Advisors Holdings LLPparent holding company1.4M1.5%2026-06-30
2026-05-1513G/Ano. 1JANUS HENDERSON GROUP PLCparent holding company4.2M4.5%2026-03-31
2026-05-1513G/Ano. 5Avoro Capital Advisors LLCinvestment adviser, other entity5.8M6.3%2026-03-31
2026-05-1513G/Ano. 5Behzad Aghazadehparent holding company, individual5.8M6.3%2026-03-31
2026-05-1513G/Ano. 3DRIEHAUS CAPITAL MANAGEMENT LLCinvestment adviser4.5M4.9%2025-12-31
2026-02-1013GWellington Management Company LLPinvestment adviser4.8M6.0%2025-12-31

13F holders

Tracked managers holding XENE at their latest 13F. JSON

8 of the 30 tracked managers held XENE at their latest 13F, $253.0M in total at quarter-end prices. Two Sigma Investments is the largest at $99.2M (0.1% of its portfolio) as of 2026-06-30. Over the prior quarter 5 added shares and 2 cut.

FundQuarterSharesValueOf portfolioChange in shares
Two Sigma Investments2026-06-301.6M$99.2M0.07%+1.0M
Citadel Advisors2026-06-301.4M$84.6M0.01%-1.3M
Millennium Management2026-06-30377K$22.7M0.01%+175K
Duquesne Family Office2026-06-30239K$14.4M0.28%0
D. E. Shaw & Co.2026-06-30224K$13.5M0.01%+205K
Renaissance Technologies2026-09-30277K$10.3M0.01%+90K
Point72 Asset Management2026-06-30130K$7.9M0.01%new
AQR Capital Management2026-06-307K$438K0.00%-16

Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.

Financials

SEC XBRL, as filed. JSON

In FY 2025 it generated -$279.1M of operating cash flow.

Cash
$119.5M
Equity
$1.24B
Total assets
$1.30B
Shares outstanding
96,840,432

Quarterly, last 8 quarters

QuarterPeriod endRevenueNet incomeMarginDiluted EPS
Q2 FY 20262026-06-30n/a-$110.7Mn/a-1.11
Q1 FY 20262026-03-31n/a-$102.3Mn/a-1.17
Q4 FY 2025derived2025-12-31n/a-$105.3Mn/an/a
Q3 FY 20252025-09-30n/a-$90.9Mn/a-1.15
Q2 FY 20252025-06-30n/a-$84.7Mn/a-1.07
Q1 FY 20252025-03-31n/a-$65.0Mn/a-0.83
Q4 FY 2024derived2024-12-31n/a-$65.7Mn/an/a
Q3 FY 20242024-09-30n/a-$62.8Mn/a-0.81

Fiscal years, with buybacks and dividends

Fiscal yearEndsRevenueNet incomeOperating cash flowCapexBuybacksDividends
FY 20252025-12-31n/a-$345.9M-$279.1M$799Kn/an/a
FY 20242024-12-31n/a-$234.3M-$181.4M$3.1Mn/an/a
FY 20232023-12-31n/a-$182.4M-$151.1M$5.6Mn/an/a
FY 20222022-12-31n/a-$125.4M-$101.0M$2.9Mn/an/a
FY 20212021-12-31n/a-$78.9M-$69.5M$2.0Mn/an/a

Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-08-03 from the cover page.

What this page is

Xenon Pharmaceuticals in the regulatory record

Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.

Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.

This page follows Xenon Pharmaceuticals (XENE), SEC CIK 1582313, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.

Source and updates

Short interest
FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-30.JSON and CSV
Daily short volume
FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-12.JSON and CSV
Fails to deliver
SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-08.JSON and CSV
Planned sales
SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-08-28.JSON and CSV
Large holders
SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-11-06.JSON and CSV
13F holders
SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
Financials
SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
Earnings dates
SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-11-09.JSON and CSV
Insider trades
SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-15.JSON and CSV
Company record
EDGAR filing index for CIK 1582313Ticker, name and exchange from the SEC's company list, refreshed weekly.
Rate limits
10 requests a minute without a key, 30 with a free key from a free account.

How to read it

  • Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
  • Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
  • Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.

Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.

Datasets

Frequently Asked Questions

How much of XENE is sold short?
7,363,365 shares were held short at the 2026-10-30 settlement, 6.4 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is XENE's daily short volume?
On 2026-11-12, 377,581 of the 532,807 XENE shares reported to FINRA were sold short, 70.9% of the day's reported volume. Short volume is a flow for one day, not a position.
Does XENE have fails to deliver?
The SEC's latest file shows 44,074 XENE shares failed to deliver at settlement 2026-10-08. Fails are reported per settlement date and published twice a month with a lag.
Are XENE insiders buying or selling?
Over the last 90 days XENE insiders reported 2 open-market buys ($1.7M) against 2 sells ($426K), so the dollar flow leans toward buying. Latest filing: Kelly Thomas Patrick (Chief Financial Officer) on 2026-10-15.
Have XENE insiders filed to sell?
17 Form 144 notices on file for XENE worth $23.1M at the prices reported; 1 in the last 90 days worth $438K. Latest: CHRISTOPHER KENNEY filed on 2026-08-28 to sell 7,068 shares ($438K) from 2026-08-28.
Who owns 5% or more of XENE?
6 holders report 5% or more of XENE in their latest filing, all on Schedule 13G (passive). The largest reported stake is Abigail P. Johnson at 11.5% of the class (11,136,649 shares), filed 2026-11-05 for an event on 2026-09-30.
What did XENE report last quarter?
In FY 2025 it generated -$279.1M of operating cash flow.
Which tracked 13F managers own XENE?
8 of the 30 tracked 13F managers held XENE shares at their latest filing, $253.0M in all. The largest: Two Sigma Investments (1.6M shares, $99.2M), Ken Griffin's Citadel Advisors (1.4M shares, $84.6M), Izzy Englander's Millennium Management (377K shares, $22.7M), Stanley Druckenmiller's Duquesne Family Office (239K shares, $14.4M), D. E. Shaw & Co. (224K shares, $13.5M), Renaissance Technologies (277K shares, $10.3M). The table above lists all 8.

Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.